GlassScriptPhysician profile
Aashit Kanubhai Shah
NPI 1326085028
$7,859.96
in general payments reported to CMS, 2019-2025
8 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2021: $1,030 · 2023: $6,114 · 2024: $44.86 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,554 · Travel and Lodging: $1,178 · Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,554.00 |
| Travel and Lodging | $1,178.48 |
| Food and Beverage | $563.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $5,950.40 | 2021-2023 | Valtoco |
| Natus Medical Incorporated | $1,000.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $534.00 | 2019 | |
| Eisai INC. | $134.47 | 2023-2024 | |
| Sk Life Science, INC. | $72.40 | 2025 | Xcopri |
| Medtronic, INC. | $65.18 | 2025 | Percept PC Brainsense |
| Neuropace, INC. | $57.29 | 2023 | |
| Livanova USA, INC. | $46.22 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aashit Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.